|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||January 01, 2019|
|Effective date (End):||October 31, 2020|
|Field of knowledge:||Agronomical Sciences - Veterinary Medicine - Animal Pathology|
|Principal researcher:||Renee Laufer Amorim|
|Grantee:||Giulia Gumiero Guiraldelli|
|Home Institution:||Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil|
Mammary gland tumors are important in Veterinary Medicine due its high incidence in non-castrated female dogs, with most cases being histologically malignant. In addition, this is the most common tumor in women, being the dog a relevant model for the comparative study in humans due its similar clinical and molecular characteristics. The PDGFR pathway has been shown to be extremely important in cancer studies, but there are few studies evaluating this pathway role in canine mammary gland tumors. Thus, this research aims to evaluate the antitumor response of Rapamycin and Sorafenib in metastatic and its primary mammary gland carcinoma cells. For this, we will evaluate the cells before and after treatment with both tyrosine kinase inhibitors using Western Blotting, gene expression, MTT ([3- (4,5-dimethylthiazol-2yl) -2,5-diphenyl tetrazolium bromide] and trypan blue bromide to evaluate the response of the different cells.